Study on the effect of plasmapheresis combined with high dose of IVIG reduces donor-specific HLA antibody titer to promote donor cell implantation in allogeneic hematopoietic stem cell transplantation

开始日期2023-11-28

申办/合作机构

西部战区总医院

JPRN-jRCT2041220136

/ Recruiting临床3期IIT

A multicenter, open-label study to investigate the efficacy and safety of GB-0998 for the treatment of neurological neuropathy in patients with Eosinophilic Granulomatosis with Polyangiitis(EGPA).

开始日期2023-01-15

申办/合作机构-

ChiCTR2200062896

/ SuspendedN/AIIT

A multicenter study of a short-course blood purification sequential reduction IVIG regimen for the treatment of severe autoimmune diseases

开始日期2022-09-01

申办/合作机构-

100 项与人免疫球蛋白(一般社団法人日本血液制剤机构) 相关的临床结果

登录后查看更多信息

100 项与人免疫球蛋白(一般社団法人日本血液制剤机构) 相关的转化医学

登录后查看更多信息

100 项与人免疫球蛋白(一般社団法人日本血液制剤机构) 相关的专利（医药）

登录后查看更多信息

8,994

项与人免疫球蛋白(一般社団法人日本血液制剤机构) 相关的文献（医药）

2025-12-31·Hematology

Sustained response off treatment after fostamatinib in refractory immune thrombocytopenia: A series of four case reports

Article

作者: Ghanima, Waleed ; Rackwitz, Stefan ; Lucas Boronat, Francisco Javier ; Carrai, Valentina

INTRODUCTION:

A goal of most primary immune thrombocytopenia (ITP) treatments is reducing or discontinuing treatment while maintaining a response including an absence of bleeding events. We present four cases describing treatment with the spleen tyrosine kinase (SYK) inhibitor, fostamatinib, that showed sustained response off treatment (SROT).

CASE PRESENTATIONS:

Case 1 was a 66-year-old male with chronic ITP. He was pre-treated with prednisone and rituximab before being in the FIT-2 clinical trial (placebo). He received fostamatinib in the FIT-3 open-label extension for seven weeks and maintained SROT for 2.5 years. Case 2 was a 54-year-old female patient with chronic, highly refractory ITP. SROT was achieved after 6 months of fostamatinib and was maintained for more than 16 months (in remission to date). Case 3 was a 60-year-old male with chronic ITP. He was successfully treated with cycles of corticosteroids for six years prior to fostamatinib. He was treated with fostamatinib plus prednisone for approximately two months. SROT was observed in this patient for one year. Case 4 was a 67-year-old male with persistent ITP. Before fostamatinib, he was unresponsive to high-dose dexamethasone, IVIG, eltrombopag and romiplostim. After 11 months of fostamatinib, his dose was tapered for three months and ultimately discontinued. SROT was observed for more than ten months (in remission to date).

DISCUSSION:

These cases emphasize that SROT is achievable with fostamatinib in complex ITP cases unresponsive to multiple previous therapies. Additional research is needed to identify the magnitude of the underlying mechanisms, and the clinical factors associated with, and potentially predictive of, SROT.

2025-12-31·Hematology

The costs of treating bleeding episodes in patients with immune thrombocytopaenia in the United Kingdom

Article

作者: McDonald, Vickie ; Pochopień, Michał ; James, Samuel ; Guterres, Sebastian ; Zakrzewski, Maja

OBJECTIVES:

Immune thrombocytopaenia (ITP) is a rare autoimmune disorder characterized by low platelet count and increased risk of bleeding. This study aimed to be the first publication to characterize the economic burden of bleeding events in patients with ITP in the UK.

METHODS:

We performed a microcosting analysis to estimate the costs associated with bleeding events in patients with ITP. Healthcare resources utilized in the management of bleeds of different severity were costed using well-established UK cost sources. The results were validated through semi-structured interviews with clinical experts.

RESULTS:

The severity of bleeding events was classified into four categories, ranging from bleeding managed at home, through mild bleeding managed in the outpatient or day case setting, to serious and life-threatening bleeding events requiring inpatient admission. Total medical costs per event ranged from £2,930 for managing a mild bleeding event, through £16,711 for a serious bleeding event to £32,461 for a life-threatening event. The major cost driver for mild and serious events were intravenous immunoglobulin (IVIg) costs, amounting to £1,614 and £8,071 for the two severity categories, respectively. For life-threatening events, the costs of intensive care unit stay (£9,089) exceeded those of IVIg (£8,071).

CONCLUSION:

Real-world costs of managing bleeding in patients with ITP in the UK are substantial and greater than costs set only based on the UK NHS Tariff. Mitigating the risk of bleeding in patients with ITP is likely to yield not only clinical advantages for patients but also offer substantial cost savings to the health system.

2025-12-31·PLATELETS

A case with a novel GATA1 variant mimicking immune thrombocytopenia attacks

Article

作者: Aktekin, Elif Habibe ; Ceylaner, Serdar ; Erbay, Ayşe ; Beşen, Şeyda ; Yazıcı, Nalan

One of the leading thrombocytopenia occasions in childhood is immune thrombocytopenia (ITP). Small number of these patients do not respond to treatment methods known to be effective for ITP such as corticosteroids, intravenous immunoglobulin and thrombopoietin receptor agonists (eltrombopag, romiplostim, etc.) and have serious bleeding symptoms. We present a case in which a molecular genetic analysis was performed due to challenging responses to medical treatment for severe systemic bleeding symptoms which were similar to ITP. A hemizygous variant was detected in the GATA1 gene and a homozygous variant in the ATP2A1 gene for Brody myopathy. Eltrombopag, romiplostim, IVIG and corticosteroid were applied to resistant thrombocytopenia of the patient without knowing the cause. Patient had response in platelet counts in some occasions. This situation attracted our attention after the detection of this GATA variant in the etiopathogenesis of thrombocytopenia. Further investigations should be performed for much more rare causes of thrombocytopenia in patients with refractory thrombocytopenia attacks.

项与人免疫球蛋白(一般社団法人日本血液制剤机构) 相关的新闻（医药）

2025-05-20

·PipelineReview

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations Poster Presentations on New Pivotal Phase 3 Analyses Underscore Tanruprubart’s Rapid and Sustained Treatment Effect and Improvement in Quality of Life Compared to Placebo BRISBANE, CA, USA I May 19, 2025 I Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today presented oral and poster presentations highlighting improved outcomes with tanruprubart (formerly ANX005) at the 2025 Peripheral Nerve Society (PNS) Annual Meeting being held May 17-20, 2025 in Edinburgh, UK. GBS is a neuromuscular emergency and rare autoimmune disease that affects at least 150,000 people worldwide each year, with no FDA-approved therapies. In its acute phase, GBS rapidly progresses toward severe weakness that can lead to sudden and complete paralysis, often requiring intensive care and mechanical ventilation. Tanruprubart is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade, with a single infusion to halt ongoing neuroinflammation and nerve damage in the early phase of GBS to improve and expedite overall recovery. “These compelling clinical results presented at PNS depict how a rapid gain in muscle strength can lead to a better state of health with a single infusion of tanruprubart in a real world setting,” said Henk-André Kroon, M.D., senior vice president of Translational Medicine at Annexon. “Currently, outcomes for GBS patients around the world remain poor, and we are grateful to our collaborators at IGOS for conducting this prespecified analysis showing the significant improvement with tanruprubart compared to standard of care. As the potential first targeted immunotherapy in GBS, we are eager to move tanruprubart forward for patients in need, with the aim of transforming the global treatment landscape for GBS.” RWE Findings Demonstrate Benefits with Tanruprubart over Current Standard of Care in Matched Patient Populations Results of the pivotal Phase 3 trial are reinforced by a RWE study that matched tanruprubart-treated patients from the pivotal Phase 3 trial with patients predominantly from western countries included in the IGOS registry who were treated with current standard of care, intravenous immunoglobulin (IVIg) or plasma exchange (PE). In the RWE study, tanruprubart showed a rapid increase in muscle function resulting in a sustained and more complete recovery compared to IVIg or PE: New Pivotal Phase 3 Trial Analyses Reinforce the Rapid and Sustained Clinical Benefits of a Single Dose of Tanruprubart Presentations are available on the publications page of the company’s website . About Tanruprubart (formerly ANX005) Annexon’s lead investigational therapy, tanruprubart, is a first-of-its kind selective, targeted and rapid-acting agent designed to reduce inflammation and nerve damage by stopping C1q activity in the peripheral and central nervous systems. In GBS, tanruprubart is designed to seek out C1q and prevent its binding to targets on peripheral nerves. Tanruprubart is administered intravenously and has been observed to act almost immediately in blocking C1q function. The aim of an effective treatment in GBS is to rapidly stop the autoimmune damage on nerve cells, allowing patients to regain muscle strength sooner and to regain independence and return to pre-illness activities. Tanruprubart has received both Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration as well as orphan drug designation from the European Medicines Agency for the treatment of GBS. About Guillain-Barré Syndrome (GBS) GBS is a rare neuromuscular emergency resulting from an acute autoantibody and classical complement-mediated attack on peripheral nerves that generally occurs post-infection in otherwise healthy persons. It is an acute, rapidly progressive disease with a narrow timeframe for therapeutic intervention. GBS results in the hospitalization of more than 22,000 people annually in the U.S. and Europe. In its acute phase, the peripheral nerve damage progresses rapidly, causing sudden and complete neuromuscular paralysis that can lead to significant morbidity, disability and mortality. Currently, there are no approved treatments for GBS in the U.S. The long-term disease burden associated with GBS has led to a multi-billion-dollar annual economic cost to the U.S. healthcare system alone. More information about the impact of GBS is available at MoveGBSForward.com . About Annexon Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com . SOURCE: Annexon Biosciences

临床结果临床3期孤儿药快速通道免疫疗法

2025-05-14

·Business Wire

Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data

MENLO PARK, Calif.--(BUSINESS WIRE)--Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today announced that the first patient has been dosed in its Phase 2 clinical trial evaluating NVG-2089 in individuals with chronic inflammatory demyelinating polyneuropathy (CIDP). The company also announced that it will present results from a Phase 1 study of NVG-2089 in healthy volunteers at the 2025 Peripheral Nerve Society (PNS) Annual Meeting on May 19th in Edinburgh, Scotland. “Dosing the first patient in our Phase 2 CIDP trial marks an important step forward in our mission to deliver targeted, mechanism-based immunomodulation for patients with autoimmune diseases,” said Alan Glicklich, M.D., Chief Medical Officer of Nuvig. “Dosing the first patient in our Phase 2 CIDP trial marks an important step forward in our mission to deliver targeted, mechanism-based immunomodulation for patients with autoimmune diseases,” said Alan Glicklich, M.D., Chief Medical Officer of Nuvig Therapeutics. “We are encouraged by the safety and pharmacodynamic data observed in our Phase 1 study and look forward to evaluating NVG-2089 in individuals living with CIDP, a condition that remains underserved by currently available therapies.” The Phase 2 study, called INVGOR, is a multicenter, global trial evaluating the safety, tolerability, and potential clinical benefit of NVG-2089 in up to 60 participants with CIDP. The trial includes patients currently treated with intravenous immunoglobulin (IVIg) who will transition to NVG-2089 and patients who have not previously been treated. The INVGOR trial is being conducted at approximately 40 sites globally. It will evaluate the safety and tolerability of NVG-2089, as well as evaluating the percentage of treatment naive patients achieving evidence of clinical improvement (ECI) at Week 14, and the percentage of IVIg treatment experienced patients achieving ECI at week 14 or stability of disease as measured by adjusted INCAT score between weeks 4 and 14. “There remains a considerable unmet need for CIDP therapies that are effective, non-immunosuppressive, well tolerated, and more convenient than current therapies,” said Jeffrey Allen, M.D., Professor of Neurology at the University of Minnesota Medical School. “We welcome the development of new treatment options such as NVG-2089 that aim to address these limitations and improve patient outcomes.” Presentation of the Phase 1 findings at the upcoming PNS meeting reflects the continued clinical momentum behind NVG-2089. In the Phase 1 study, NVG-2089 was well tolerated, with no serious adverse events, no severe adverse events, and no discontinuations due to adverse events. About NVG-2089 NVG-2089 is a recombinant human IgG1-Fc fusion protein designed to mimic the key immunomodulatory mechanisms of intravenous immunoglobulin (IVIg), the current standard of care for a range of autoimmune diseases. Unlike plasma-derived IVIg, NVG-2089 is produced recombinantly, offering the potential for improved consistency, scalability, and patient convenience. By selectively engaging anti-inflammatory pathways without broadly suppressing the immune system, NVG-2089 is being developed as a next-generation alternative to IVIg with the goal of addressing its limitations in supply, tolerability, and administration burden. About Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms. Symptoms typically include symmetrical muscle weakness leading to difficulties with walking, climbing stairs, and performing fine motor tasks. Sensory disturbances such as numbness, tingling, or burning sensations. Additionally, diminished or absent reflexes are a common clinical finding. Fatigue is frequent, significantly impacting the patient’s quality of life. CIDP symptoms can vary in severity and may progress over several months. Diagnosis is typically confirmed through nerve conduction studies, which reveal demyelination, and cerebrospinal fluid analysis showing elevated protein levels. About Nuvig Therapeutics Nuvig Therapeutics is a clinical-stage biotechnology company that is advancing an innovative and transformational pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases. The Company’s lead investigational drug candidate, NVG-2089, is an engineered Fc fragment designed to precisely target type II Fc receptors. When NVG-2089 binds to its target, it upregulates the expression of FcgRIIb and causes the expansion of T regulatory cells and the downregulation of numerous inflammatory pathways. Nuvig is based in Menlo Park, California. For more information, please visit www.nuvigtherapeutics.com.

临床1期免疫疗法临床2期临床结果

2025-05-14

·PRNewswire

Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS

LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS) Annual Meeting, taking place 17-20 May in Edinburgh, Scotland. Hansa communicated the results from the 15-HMedIdeS-09 study in December 2024. Professor Shahram Attarian, Head of Department of Neuromuscular Diseases and ALS, Hopitaux Universitaires de Marseille (APHM) and International Coordinating Principal Investigator will present data from 15-HMedIdeS-09 Phase 2 study at the 2025 PNS Annual Meeting. Hitto Kaufmann, Chief R&D Officer, Hansa Biopharma said, "We are pleased to be able to share more detail around the positive data from our 15-HMedIdeS-09 Phase 2 study, which demonstrated the significant potential imlifidase could have in combination with standard of care IVIg for patients with GBS. We know that IgG is a key driver of inflammatory attacks on peripheral nerves and has been clinically linked to the severity and progression of GBS, and that there is a clear and urgent need for new and faster treatment options in GBS. This data offers meaningful insights to help advance the understanding of IgG in GBS and improve patient care." Hansa's Phase 2 15-HMedIdes-09 open-label, single arm study was performed across multi-centers in the UK, France, and the Netherlands evaluating the safety, tolerability, and efficacy of a single dose of imlifidase (0.25 mg/kg) in 30 adult GBS patients in combination with standard of care (SoC) intravenous immunoglobulin (IVIg). The administration of imlifidase prior to SoC in patients with GBS was considered to be safe and well tolerated. --- ENDS --- Contacts for more information: Evan Ballantyne, Chief Financial Officer [email protected] Stephanie Kenney, VP Global Corporate Affairs [email protected] Notes to editors About imlifidase Imlifidase is a unique antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets IgG and inhibits IgG-mediated immune response.1 It has a rapid onset of action, cleaving IgG-antibodies and inhibiting their activity within hours after administration. Imlifidase has conditional marketing approval in Europe and is marketed under the trade name IDEFIRIX® for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.1 About imlifidase and autoimmune diseases Autoimmune diseases form a group of serious diseases caused by the immune system attacking the body. In many autoimmune diseases the immune system mistakenly recognizes the body's own proteins, as foreign and mounts an immune response, creating antibodies to attack the body's own cells and tissues.2-4 Pathogenic IgG can contribute to a broad spectrum of autoimmune diseases. Hansa Biopharma is exploring how imlifidase and HNSA-5487 may be able to prevent or slow the progression of these diseases and their debilitating, life-threatening symptoms. Imlifidase is currently being studied in the following autoimmune diseases: anti-glomerular basement membrane (anti-GBM) disease and Guillain-Barré Syndrome (GBS). HNSA-5487 is moving quickly into the clinical phase focusing on patients with myasthenia gravis (MG) and potentially other neuro-autoimmune diseases. About Guillain-Barré Syndrome Guillain-Barré Syndrome (GBS) is a rare, acute, paralyzing, inflammatory disease of the peripheral nervous system caused by the immune system damaging nerve cells and structures. It affects 1-2 in 100,000 people annually.5 In GBS, rapid onset and progression of muscle weakness occurs and can lead to severe paralysis of the arms and legs. Approximately 25 percent of patients require mechanical ventilation for days to months and 20 percent are unable to walk after six months.6-8 Even with current standard of care - either plasma exchange or IVIg therapy - GBS is fatal in 3-7% of cases.6-8 Most GBS patients also have sensory disturbance (tingling or numbness or ataxia) and pain, and some patients have double vision or problems with swallowing. GBS may also involve the respiratory muscles, leading to intensive care unit (ICU) admission and mechanical ventilation.9 About Hansa Biopharma Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at and follow us on LinkedIn. ©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved. References European Medicines Agency. Idefirix® summary of product characteristics. Available at: . Angum F, et al. The Prevalence of Autoimmune Disorders in Women: A Narrative Review. Cureus. 2020 May 13;12(5):e8094. doi: 10.7759/cureus.8094. Wang L, et al. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015 Oct;278(4):369-95. doi: 10.1111/joim.12395. Ma H, Murphy C, Loscher CE and O'Kennedy R (2022) Autoantibodies – enemies, and/or potential allies? Front. Immunol. 13:953726. doi: 10.3389/fimmu.2022.953726 McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150-63. doi: 10.1159/000184748. Epub 2008 Dec 17. PMID: 19088488.Fletcher D, et al. Neurology. 2000 27;54(12):2311-5 Leonhard SE, Papri N, Querol L, Rinaldi S, Shahrizaila N, Jacobs BC. Guillain-Barré syndrome. Nat Rev Dis Primers. 2024 Dec 19;10(1):97. doi: 10.1038/s41572-024-00580-4. PMID: 39702645. Fletcher DD, Lawn ND, Wolter TD, Wijdicks EF. Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation. Neurology. 2000;54(12):2311–5. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014 Aug;10(8):469-82. doi: 10.1038/nrneurol.2014.121. Epub 2014 Jul 15. PMID: 25023340. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717-27. doi: 10.1016/S0140-6736(16)00339-1. Epub 2016 Mar 2. PMID: 26948435. This information was brought to you by Cision The following files are available for download: SOURCE Hansa Biopharma AB WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床结果上市批准

100 项与人免疫球蛋白(一般社団法人日本血液制剤机构) 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
器官移植排斥	日本	The Japan Blood Products Organization	2024-09-24
格林-巴利综合征	日本	The Japan Blood Products Organization	2017-02-08
大疱性类天疱疮	日本	The Japan Blood Products Organization	2016-07-27
中耳炎	日本	The Japan Blood Products Organization	2015-02-02
天疱疮	日本	The Japan Blood Products Organization	2013-08-05
重症肌无力	日本	The Japan Blood Products Organization	2011-09-26
慢性炎症性脱髓鞘性多发性神经病	日本	The Japan Blood Products Organization	2011-02-07
皮肌炎	日本	The Japan Blood Products Organization	2010-10-27
多发性肌炎	日本	The Japan Blood Products Organization	2010-10-27
粘膜皮肤淋巴结综合征	日本	The Japan Blood Products Organization	1996-01-31
丙种球蛋白缺乏血症	日本	The Japan Blood Products Organization	1991-06-28
感染	日本	The Japan Blood Products Organization	1991-06-28
免疫性血小板减少症	日本	The Japan Blood Products Organization	1991-06-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
习惯性流产	临床3期	日本	The Japan Blood Products Organization	2014-06-03
终末期肾脏病	临床3期	日本	The Japan Blood Products Organization	2013-11-01
自身免疫性疾病	临床前	美国	Vanderbilt University School of Medicine	2012-10-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EHA2024	N/A	-	25	IVIG 400mg/kg	選夢繭鹹齋遞獵積簾襯(膚繭齋餘夢衊齋衊遞醖) = 衊鑰齋憲艱觸願鑰鹹膚獵鏇範艱範齋簾蓋遞窪 (糧願憲繭淵簾鏇衊鹽範, 1 ~ 000-10 to 500) 更多	积极	2024-05-14
EHA2024	N/A	-	25	Dexamethasone 10mg/m2	選夢繭鹹齋遞獵積簾襯(膚繭齋餘夢衊齋衊遞醖) = 積遞範夢願範衊願衊顧獵鏇範艱範齋簾蓋遞窪 (糧願憲繭淵簾鏇衊鹽範, 1 ~ 000-10 to 500) 更多	积极	2024-05-14
ASH2023	N/A	血小板减少症	651	IVIG	鹽窪襯願衊繭夢齋淵廠(鏇艱鹽範窪糧夢選鹽衊) = 艱網鹽獵鑰繭衊襯餘衊憲製艱齋夢廠鑰夢網窪 (淵憲鹹膚襯簾餘糧糧夢 ) 更多	-	2023-12-10
ISN WCN2023	N/A	多瘤病毒感染	-	IVIG	鹹餘糧衊願遞鑰範顧鹽(憲願衊顧顧願醖淵選獵) = 製衊遞醖襯艱網壓選積觸簾淵觸衊繭構夢鏇範 (鹹襯鹽鑰願顧齋艱製繭 ) 更多	-	2023-03-01
ISN WCN2023	N/A	多瘤病毒感染	-	No IVIG	鹹餘糧衊願遞鑰範顧鹽(憲願衊顧顧願醖淵選獵) = 顧積範範遞憲範製鹹顧觸簾淵觸衊繭構夢鏇範 (鹹襯鹽鑰願顧齋艱製繭 ) 更多	-	2023-03-01
AAAAI2023	N/A	decreased IgA levels \| concurrent treatment with an immunomodulating agent \| prior reported drug-allergy ... 更多	15	IVIG infusion	築鹹網壓簾顧積窪膚壓(艱鬱構衊廠遞顧鏇膚廠) = 網蓋襯選醖艱蓋遞製遞獵顧夢衊蓋鬱構構蓋糧 (糧遞願鑰積獵範鏇鹽構 )	积极	2023-02-01
AAO2022	N/A	疼痛 \| 周围神经系统疾病 auto-/dysimmune antibodies	-	IVIG	遞選製餘遞鏇廠簾獵鏇(糧艱醖衊衊鬱構範鑰膚) = Four patients discontinued treatment before follow-up due to side effects 齋範鏇窪繭憲齋艱醖繭 (夢簾齋糧鹹繭遞淵鹽遞 ) 更多	积极	2022-09-29
AAN2022	N/A	肌肉无力	-	IVIG	鏇顧簾選夢憲夢鑰積鬱(憲憲選糧壓糧齋糧艱觸) = 糧廠鏇鏇築構鑰範膚蓋鏇餘憲選餘鏇願製願積 (窪獵淵築夢鹹鹽願繭製, 1.19 ~ 2.10)	-	2022-05-03
AAN2022	N/A	肌肉无力	-	IVIG	繭選簾選夢鏇憲廠鹽鬱(網顧願鹹網構壓窪網襯) = 製糧窪憲鹹餘獵夢夢鏇網構鑰遞淵顧膚鹽築膚 (淵獵壓選窪顧齋壓襯夢 ) 更多	-	2022-05-03
ProCID study (AAN2022)	N/A	慢性炎症性脱髓鞘性多发性神经病	142	High dose IVIG (2.0g/kg)	鬱觸衊廠壓鏇衊夢範鹹(壓齋襯憲衊繭齋糧壓鹹) = allergic dermatitis 壓齋繭鏇鬱齋艱鹽鹽餘 (願憲鹽壓襯醖選窪餘壓 ) 更多	-	2022-05-03
AAAAI2022	N/A	免疫缺陷综合征	53	PCV13IVIG (PCV13 vaccination)	觸獵顧蓋夢簾鬱夢鑰鑰(齋艱壓糧獵衊壓築壓製) = 範夢襯夢窪築餘醖簾鹽簾選簾製選醖鑰衊鏇窪 (構糧夢鑰窪網選簾獵鏇 )	-	2022-02-01
AAAAI2022	N/A	免疫缺陷综合征	53	PPSV23IVIG (PPSV23 vaccination)	遞艱選齋膚夢廠衊簾鬱(願顧糧觸觸簾範繭積築) = 艱憲窪範衊糧鑰蓋鹽衊鬱繭獵衊廠憲鹽築願襯 (淵願鏇憲廠積願夢襯選 )	-	2022-02-01
P4.9-033 (AAN2019)	N/A	西尼罗河热	2	IVIG	餘衊簾膚觸顧衊築襯構(鏇鬱艱鹹網膚範衊鏇繭) = Both OMA and MRI changes resolved significantly with 2 sessions of IVIG 廠選鑰網鏇鹽膚構簾糧 (餘鹹壓夢繭蓋窪蓋糧窪 ) 更多	积极	2019-04-09
P5.2-072 (AAN2019)	N/A	anti-aquaporin 4 (AQP4) antibodies \| anti-myelin oligodendrocyte glycoprotein (MOG) antibodies \| anti-Human 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCR) antibodies ... 更多	-	IVIg preparations	鹽醖廠獵襯觸餘鹽鑰醖(廠鹹鏇鏇醖網鬱襯願齋) = 鑰淵餘壓艱構夢簾鑰積網顧艱網鏇遞艱廠窪衊 (獵繭範壓構衊糧觸艱繭, 41 ~ 816)	-	2019-04-09